Indian authorities probe bribery claim in toxic cough syrup tests

"I just want the matter formally investigated," said the 38-year-old, adding that he was waiting to be asked to submit an affidavit that would trigger such a probe

India cough syrup, new drug policy
Reuters
2 min read Last Updated : Jun 13 2023 | 10:29 PM IST
Authorities have launched an inquiry into an allegation that a local pharmaceutical regulator, in return for a bribe, helped switch samples of cough syrups that the World Health Organization (WHO) had linked to the deaths of children in Gambia before the samples were tested at an Indian laboratory, according to two government officials and documents reviewed by Reuters.
 
In an April 29 letter to the Anti-Corruption Bureau in Haryana state reviewed by Reuters, a lawyer named Yashpal accused the state’s drug controller, Manmohan Taneja, of taking a bribe of ~5 crore ($605,419) from local manufacturer Maiden Phar­maceuticals to help it switch the samples before an Indian government laboratory tested them. Maiden’s factory is based in Haryana.
 
Reuters was unable to independently establish that any bribes were paid.
 
Taneja did not respond to phone calls, messages or emails seeking comment. Maiden did not respond to requests for comment. The WHO said it had no knowledge of the allegation.
 
Yashpal, who like some Indians uses only one name, did not say in the letter where he got the information, or provide evidence for his claim about the syrups made by Maiden.
 
The lawyer said he had learned about the alleged bribe in the Maiden case from at least two individuals in the pharmaceutical industry, including one within Maiden, but declined to identify any of them for fear of retribution.
 
"I just want the matter formally investigated," said the 38-year-old, adding that he was waiting to be asked to submit an affidavit that would trigger such a probe.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Cough syrupBribery

First Published: Jun 13 2023 | 10:29 PM IST

Next Story